Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide-induced bladder carcinogenesis and enhancement of forestomach carcinogenesis

Carcinogenesis
G MurasakiS M Cohen

Abstract

N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide (FANFT) is a potent urinary bladder carcinogen in the rat, and it can be metabolically activated in vitro by a variety of enzyme systems including aerobic cooxidation by prostaglandin H synthase. The latter enzyme is present in the rat bladder mucosa and can be inhibited by the oral administration of aspirin (ASA). To determine if ASA could inhibit the bladder carcinogenicity of FANFT, FANFT (0.2%) was co-administered in the diet with ASA (0.5%) for 12 weeks followed by 1 week of ASA only and then 56 weeks on control diet. 0.2% FANFT followed by control diet induced bladder carcinomas in 18 of 21 (87%) rats, but when ASA was co-administered, only 10 of 27 (37%) rats developed bladder carcinoma (p less than 0.001). However, forestomach tumors, not seen in rats fed only FANFT, developed in 7 rats fed FANFT plus ASA. No tumors occurred in control rats or those fed only ASA. Possible mechanisms, including the role of prostaglandin H synthase in FANFT metabolism, are discussed.

Citations

Feb 14, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K S ChoiS J Kim
Jan 1, 1994·Journal of Cellular Biochemistry. Supplement·G J KelloffG G Knapp
Jan 1, 1992·Teratogenesis, Carcinogenesis, and Mutagenesis·N Ito, K Imaida
Dec 1, 1994·Cancer Metastasis Reviews·L J Marnett
Jan 1, 1993·Journal of Cancer Research and Clinical Oncology·R KlänT Meier
Jan 1, 1991·Chemico-biological Interactions·B J SmithT E Eling
Oct 1, 1986·Toxicology and Applied Pharmacology·S L JohanssonS M Cohen
Jan 1, 1990·Journal of Pharmaceutical and Biomedical Analysis·M B MattammalB B Davis
Feb 19, 2004·Urologic Oncology·William A BlumentalsThomas J Mason
Feb 26, 2000·BJU International·A F Badawi
Nov 12, 1998·Journal of the National Cancer Institute·M M Taketo
Sep 1, 1985·The Journal of Clinical Investigation·L A SpryB B Davis
Aug 21, 2001·Biological & Pharmaceutical Bulletin·M NiikawaH Nagase
Jan 1, 1991·Drug Metabolism and Drug Interactions·M StiborováP Anzenbacher
Nov 1, 2007·Expert Opinion on Investigational Drugs·Konstantinos GiannitsasPetros Perimenis
May 8, 2007·Urologic Oncology·Dominique S Michaud
Nov 13, 2015·Thrombosis and Haemostasis·Victor L SerebruanyMoo Hyun Kim
Jun 5, 2004·Seminars in Oncology·Anita L Sabichi, Scott M Lippman
Jan 1, 1990·Critical Reviews in Biochemistry and Molecular Biology·F P Guengerich
Jun 8, 1999·Japanese Journal of Cancer Research : Gann·Y UshidaH Tsuda
Jan 1, 1988·Annals of the New York Academy of Sciences·P J O'Brien
Apr 11, 1997·The Journal of Biological Chemistry·Z DongW Y Ma
Jun 18, 2004·Cancer Investigation·Charles Blanke
Aug 1, 1987·Cancer·W F MaloneP Greenwald
Feb 13, 2010·Neuro-oncology·Marie-Thérése StockhausenHans Skovgaard Poulsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.